Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.
Am J Transplant
; 18(6): 1424-1434, 2018 06.
Article
em En
| MEDLINE
| ID: mdl-29226570
Palavras-chave
clinical research/practice; immunosuppressant - calcineurin inhibitor (CNI); immunosuppressant - fusion proteins and monoclonal antibodies: alemtuzumab; immunosuppressant - fusion proteins and monoclonal antibodies: basiliximab/daclizumab; immunosuppressant - mechanistic target of rapamycin (mTOR); immunosuppression/immune modulation; kidney transplantation/nephrology
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transplante Homólogo
/
Inibidores de Calcineurina
/
Alemtuzumab
/
Imunossupressores
/
Nefropatias
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article